ECTRIMS 2024 | Natalizumab versus anti-CD20 monoclonal antibodies in the treatment of MS

Maya Zeineddine, PharmD, Lebanese American University, Byblos, Lebanon, discusses the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in multiple sclerosis (MS). She highlights that they differ in mechanism of action, route of administration, and side effect profile, but data comparing their efficacy is lacking. This interview took place at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024) in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.